Evidence map›Paper›PMID 23177740›Full record

ArticleMolecular cell2013

Genome-wide methylation profiles reveal quantitative views of human aging rates.

Gregory Hannum, Justin Guinney, Ling Zhao, Li Zhang, Guy Hughes, SriniVas Sadda, Brandy Klotzle, Marina Bibikova, Jian-Bing Fan, Yuan Gao and 6 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in Molecular cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2,530 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2,530citing papers in PubMed, 3 pooled it
29.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03353597 phase1 / phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects

TypeinterventionalSponsorChandra DuggiralaRan2018 to 2022Enrolled2,120ConditionsAgingArmsPlasma Transfusion
NCT05110313 phase4completednot on this mapstarted 2022, after this paper: background citation

Effects of Tildrakizumab (ILUMYA) Use on Epigenetic Age Acceleration and Psoriasis

TypeinterventionalSponsorCarlos WambierRan2022 to 2024Enrolled30ConditionsPsoriasis, Aging, Epigenetic Disorder, InflammationArmsTILDRAKIZUMAB
3 · Its place in the literature

Who cites it

2,530 citing papers in PubMed, 3 syntheses or guidelines pooled it, 4,325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

2,470 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 2 countries.

Gregory Hannum *Department of Bioengineering, University of California, San Diego, CA 92093, USA.
Justin Guinney *Sage Bionetworks, Seattle, WA 98109, USA.
Ling ZhaoMolecular Medicine Research Center and Department of Ophthalmology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Li ZhangMolecular Medicine Research Center and Department of Ophthalmology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
Guy HughesInstitute for Genomic Medicine, University of California, San Diego, CA 92093, USA.
SriniVas SaddaDoheny Eye Institute, University of Southern California, Los Angeles, CA 90033, USA.
Brandy KlotzleIllumina Incorporation, San Diego, CA 92122, USA.
Marina BibikovaIllumina Incorporation, San Diego, CA 92122, USA.
Jian-Bing FanIllumina Incorporation, San Diego, CA 92122, USA.
Yuan GaoLieber Institute, Johns Hopkins University, Baltimore, MD 21205, USA.
Rob DecondeDepartment of Bioengineering, University of California, San Diego, CA 92093, USA.
Menzies ChenDepartment of Bioengineering, University of California, San Diego, CA 92093, USA.
Indika RajapakseDivision of Basic Sciences and Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, WA 98110, USA.
Stephen FriendSage Bionetworks, Seattle, WA 98109, USA.
Trey IdekerDepartment of Bioengineering, University of California, San Diego, CA 92093, USA.
Kang ZhangMolecular Medicine Research Center and Department of Ophthalmology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
University of California, San Diego · USIllumina (United States) · USSage Bionetworks · USFred Hutch Cancer Center · USJohns Hopkins University · USSichuan University · CNUniversity of Southern California · US

Funding

Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2000 to 2021
$37.7M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007198 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHI, NEIL C, INSEL, PAUL A · 1985 to 2024
$29.3M
SYNTHETIC SYSTEMSP50GM085764 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HASTY, JEFF M, IDEKER, TREY · 2010 to 2018
$23.3M
A Systems Approach to Mapping the DNA Damage ResponseR01ES014811 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IDEKER, TREY · 2005 to 2021
$8.6M
Regeneration of Retinal Neurons by Chemically Induced Reprogramming of Muller GliR01EY021374 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DING, SHENG, REH, THOMAS A · 2010 to 2014
$4.2M
ELOVL4 and Retinal DiseaseR01EY014428 · NEI · UNIVERSITY OF UTAH · PI ZHANG, KANG · 2002 to 2011
$3.4M
Genetics and Functional Studies of Age-Related Macular DegenerationR01EY018660 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, KANG · 2008 to 2012
$2.0M
Genetic Susceptibility for Development of Proliferative Diabetic RetinopathyR01EY019270 · NEI · DOHENY EYE INSTITUTE · PI SADDA, SRINIVAS R, ZHANG, KANG · 2009 to 2010
$809k
NEI NIH HHS EY014428NEI NIH HHS EY018660NEI NIH HHS EY019270NEI NIH HHS EY021374NEI NIH HHS R01 EY014428NEI NIH HHS R01 EY018660NEI NIH HHS R01 EY019270NEI NIH HHS R01 EY021374NIEHS NIH HHS R01 ES014811NIGMS NIH HHS P50 GM085764NIGMS NIH HHS P50GM085764,NIGMS NIH HHS T32 GM007198NIMH NIH HHS P30 MH062261PHS HHS R01E5014811
6 · The paper itself

Abstract

The ability to measure human aging from molecular profiles has practical implications in many fields, including disease prevention and treatment, forensics, and extension of life. Although chronological age has been linked to changes in DNA methylation, the methylome has not yet been used to measure and compare human aging rates. Here, we build a quantitative model of aging using measurements at more than 450,000 CpG markers from the whole blood of 656 human individuals, aged 19 to 101. This model measures the rate at which an individual's methylome ages, which we show is impacted by gender and genetic variants. We also show that differences in aging rates help explain epigenetic drift and are reflected in the transcriptome. Moreover, we show how our aging model is upheld in other human tissues and reveals an advanced aging rate in tumor tissue. Our model highlights specific components of the aging process and provides a quantitative readout for studying the role of methylation in age-related disease.

Indexed as

DNA MethylationGenome, HumanAdultAgedAged, 80 and overAgingEpigenesis, GeneticFemaleGenome-Wide Association StudyHumansMaleMiddle AgedModels, GeneticPhenotypeSequence Analysis, DNATranscriptome

Identifiers

PMID23177740
PMCPMC3780611
OpenAlexW2121091193

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.